Yes we are all frustrated at Race with the delay in the clinical program. The only real positive is it has enabled us to speed up other programs and steps. In biotech there is so much you don't control (or know) and you just have to make the best of the situation at every point.
The good news is bisantrene is yet to disappoint in either the clinic or lab. I am sure you would all rather a slightly delayed clinical program rather than an on-time clinical program where the drug crashes out for safety concerns or a lack of efficacy (i.e. business as usual).
RAC Price at posting:
$1.27 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)